RXRX
Recursion Pharmaceuticals Inc
NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY
$3.30
-3.23% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
14.3M
Recursion Pharmaceuticals Inc (RXRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-57.04M | $-45.40M | $-158.61M | $-83.52M | $-287.78M | $-359.17M | $-371.81M |
| Capital expenditures | $3.91M | $6.74M | $39.80M | $37.36M | $11.96M | $13.70M | $6.47M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $1.39M | $4.29M | $14.84M | $27.91M | $53.50M | $81.69M | $111.22M |
| Free cash flow | $-60.95M | $-52.13M | $-198.41M | $-120.88M | $-299.74M | $-372.87M | $-378.28M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $28.18M | — | — | — | — |